Mouse models for pre-clinical drug testing in leukemia

References

• Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236.
   PubMed Web of Science ®Google Scholar
• Theocharides APA, Rongvaux A, Fritsch K, et al. Humanized hemato-lymphoid system mice. Haematologica. 2016;101(1): 5–19.
   PubMed Web of Science ®Google Scholar
• Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science. 1988;242(4886):1706–1709.
   PubMed Web of Science ®Google Scholar
• Issacson JH, Cattanach BM. Report. Mouse News Lett. 1962;27:31.
   Google Scholar
• Nara N, Miyamoto T. Direct and serial transplantation of human acute myeloid leukaemia into nude mice. Br J Cancer. 1982;45(5):778–782.
   PubMed Web of Science ®Google Scholar
• Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature. 1983;301(5900):527–530.
   PubMed Web of Science ®Google Scholar
• McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988;241(4873):1632–1639.
   PubMed Web of Science ®Google Scholar
• Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855–867.
   PubMed Web of Science ®Google Scholar
• Mosier DE, Stell KL, Gulizia RJ, et al. Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med. 1993;177(1):191–194.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154(1):180–191.
   PubMed Web of Science ®Google Scholar
• Koyanagi Y, Tanaka Y, Tanaka R, et al. High levels of viremia in hu-PBL-NOD-scid mice with HIV-1 infection. Leukemia. 1997;11 Suppl 3:109–112.
   PubMedGoogle Scholar
• Hesselton RM, Greiner DL, Mordes JP, et al. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis. 1995;172(4):974–982.
   PubMed Web of Science ®Google Scholar
• Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175–3182.
   PubMed Web of Science ®Google Scholar
• Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304(5667):104–107.
   PubMed Web of Science ®Google Scholar
• Strowig T, Rongvaux A, Rathinam C, et al. Transgenic expression of human signal regulatory protein alpha in Rag2-/-gamma(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A. 2011;108(32):13218–13223.
   PubMed Web of Science ®Google Scholar
• Rongvaux A, Takizawa H, Strowig T, et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol. 2013;31:635–674.
   PubMed Web of Science ®Google Scholar
• Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14(6):824–837.
   PubMed Web of Science ®Google Scholar
• McIntosh BE, Brown ME, Duffin BM, et al. Nonirradiated NOD,B6.SCID Il2rγ-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Rep. 2015;4(2):171–180.
   PubMed Web of Science ®Google Scholar
• Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology. 2013;435(1):14–28.
   PubMed Web of Science ®Google Scholar
• Kamel-Reid S, Letarte M, Sirard C, et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989;246(4937):1597–1600.
   PubMed Web of Science ®Google Scholar
• Kawata A, Yoshida M, Okazaki M, et al. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res. 1994;54(10):2688–2694.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–648.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426–5435.
   PubMed Web of Science ®Google Scholar
• Ailles LE, Gerhard B, Kawagoe H, et al. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94(5):1761–1772.
   PubMed Web of Science ®Google Scholar
• Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006;24:657–679.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106(5):1565–1573.
   PubMed Web of Science ®Google Scholar
• Queudeville M, Seyfried F, Eckhoff SM, et al. Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling. Cell Death Dis. 2012;3:e364.
   PubMed Web of Science ®Google Scholar
• Castro Alves C, Terziyska N, Grunert M, et al. Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood. 2012;119(18):4224–4227.
   PubMed Web of Science ®Google Scholar
• Wallington-Beddoe CT, Don AS, Hewson J, et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PloS one. 2012;7(5):e36429.
   PubMed Web of Science ®Google Scholar
• Bhadri VA, Cowley MJ, Kaplan W, et al. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia. BMC Genomics. 2011;12:565.
   PubMed Web of Science ®Google Scholar
• Doulatov S, Notta F, Laurenti E, et al. Hematopoiesis: a human perspective. Cell Stem Cell. 2012;10(2): 120–136.
   PubMed Web of Science ®Google Scholar
• Gille C, Orlikowsky TW, Spring B, et al. Monocytes derived from humanized neonatal NOD/SCID/IL2Rγ(null) mice are phenotypically immature and exhibit functional impairments. Hum Immunol. 2012;73(4):346–354.
   PubMed Web of Science ®Google Scholar
• Cosgun KN, Rahmig S, Mende N, et al. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell. 2014;15(2):227–238.
   PubMed Web of Science ®Google Scholar
• Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 2015;125(17):2630–2640.
   PubMed Web of Science ®Google Scholar
• Wunderlich M, Chou FS, Link KA, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24(10):1785–1788.
   PubMed Web of Science ®Google Scholar
• Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3): 379–392.
   PubMed Web of Science ®Google Scholar
• Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res. 2011;71(23):7141–7144.
   PubMed Web of Science ®Google Scholar
• Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev. 2013;32(1–2):63–76. doi:10.1007/s10555-012-9405-5.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Estrov Z, Kantarjian H, et al. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998;16(4):1526–1531.
   PubMed Web of Science ®Google Scholar
• Maurer J, Janssen JW, Thiel E, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet. 1991;337(8749):1055–1058.
   PubMed Web of Science ®Google Scholar
• Voncken JW, Van Schaick H, Kaartinen V, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell. 1995;80(5):719–728.
   PubMed Web of Science ®Google Scholar
• Andrieu V, Radford-Weiss I, Troussard X, et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol. 1996;92(4):855–865.
   PubMed Web of Science ®Google Scholar
• Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96(6):2108–2115.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001;98(18):10398–10403.
   PubMed Web of Science ®Google Scholar
• McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 2005;19(5):687–706.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
   PubMed Web of Science ®Google Scholar
• Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17(3):1071–1079.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266.
   PubMed Web of Science ®Google Scholar
• Greenblatt S, Li L, Slape C, et al. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood. 2012;119(12):2883–2894.
   PubMed Web of Science ®Google Scholar
• Li L, Piloto O, Nguyen HB, et al. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008;111(7):3849–3858.
   PubMed Web of Science ®Google Scholar
• Mupo A, Celani L, Dovey O, et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013;27(9):1917–1920.
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang Y, Sha K, et al. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia. Cell Physiol Biochem. 2014;33(1):78–87.
   PubMed Web of Science ®Google Scholar
• Andreasson P, Schwaller J, Anastasiadou E, et al. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet. 2001;130(2):93–104.
   PubMed Web of Science ®Google Scholar
• Bernardin F, Yang Y, Cleaves R, et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res. 2002;62(14):3904–3908.
   PubMed Web of Science ®Google Scholar
• Fischer M, Schwieger M, Horn S, et al. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene. 2005;24(51):7579–7591.
   PubMed Web of Science ®Google Scholar
• Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319(5861):336–339.
   PubMed Web of Science ®Google Scholar
• Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A. 1988;85(14):5166–5170.
   PubMed Web of Science ®Google Scholar
• Duque-Afonso J, Feng J, Scherer F, et al. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia. J Clin Invest. 2015;125(9): 3667–3680.
   PubMed Web of Science ®Google Scholar
• Yu H, Li Y, Gao C, et al. Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia. 2010;24(5):1077–1080.
   PubMed Web of Science ®Google Scholar
• Cutts BA, Sjogren A-KM, Andersson KME, et al. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood. 2009;114(17):3629–3632.
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–823.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang T, Hu Z, et al. Efficient RNA/Cas9-mediated genome editing in Xenopus tropicalis. Development. 2014;141(3):707–714.
   PubMed Web of Science ®Google Scholar
• Yasue A, Mitsui SN, Watanabe T, et al. Highly efficient targeted mutagenesis in one-cell mouse embryos mediated by the TALEN and CRISPR/Cas systems. Sci Rep. 2014;4:5705.
   PubMed Web of Science ®Google Scholar
• Gratz SJ, Wildonger J, Harrison MM, et al. CRISPR/Cas9-mediated genome engineering and the promise of designer flies on demand. Fly. 2013;7(4):249–255.
   PubMed Web of Science ®Google Scholar
• Valletta S, Dolatshad H, Bartenstein M, et al. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget. 2015;6(42):44061–44071.
   PubMed Web of Science ®Google Scholar
• Heckl D, Kowalczyk MS, Yudovich D, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32(9):941–946.
   PubMed Web of Science ®Google Scholar
• Aubrey BJ, Kelly GL, Kueh AJ, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10(8):1422–1432.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105(1):324–334.
   PubMed Web of Science ®Google Scholar
• Giotopoulos G, van der Weyden L, Osaki H, et al. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med. 2015;212(10): 1551–1569.
   PubMed Web of Science ®Google Scholar
• Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Disc. 2006;5(9):741–754.
   PubMed Web of Science ®Google Scholar
• Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658): 404–407.
   PubMed Web of Science ®Google Scholar
• Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1(2–3):78–82.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–1552.
   PubMed Web of Science ®Google Scholar
• Annesley CE, Brown P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol. 2015;6(2):61–79.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med. 2006;354(24):2594–2596.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175–5181.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276–283.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002–1009.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review. Core Evid. 2009;4:207–213.
   Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–2541.
   PubMed Web of Science ®Google Scholar
• Kaur P, Feldhahn N, Zhang B, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007;6:67.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242–2249.
   PubMed Web of Science ®Google Scholar
• Ursan ID, Jiang R, Pickard EM, et al. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015;21(2):114–122.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica. 2007;92(9):1238–1241.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412.
   PubMed Web of Science ®Google Scholar
• Ariad suspends ponatinib sales. Cancer Discov. 2014;4(1):6–7. Available from: http://cancerdiscovery.aacrjournals.org/content/4/1/6.3.long. PMID:24402926. doi:10.1158/2159-8290.CD-NB2013-163.
   Web of Science ®Google Scholar
• Abujamra AL, Dos Santos MP, Roesler R, et al. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res. 2010;34(6): 687–695.
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013–3022.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hao C, Wang L, et al. Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors. Oncol Targets Ther. 2013;6:733–740.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105(3):959–967.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84 Suppl 1:61–66.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30(18):2204–2210.
   PubMed Web of Science ®Google Scholar
• Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. 2010;17(5): 427–442.
   PubMed Web of Science ®Google Scholar
• Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4(4):505–524.
   PubMed Web of Science ®Google Scholar
• Taylor SJ, Dagger SA, Thien CBF, et al. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood. 2012;120(19):4049–4057.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294–3301.
   PubMed Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510–3518.
   PubMed Web of Science ®Google Scholar
• Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A. 2003;100(25):15113–15118.
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021–3032.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–5187.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333–347.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9): 3132–3142.
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9): 3143–3150.
   PubMed Web of Science ®Google Scholar
• Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta. 1998;1400(1–3):301–319.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Cytochrome P450 humanised mice. Hum Genomics. 2004;1(4):300–306.
   PubMedGoogle Scholar
• Scheer N, Wolf CR. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica. 2014;44(2):96–108.
   PubMed Web of Science ®Google Scholar